Back to top

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 ...

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Quantum Biopharma Ltd. (QNTM)